Clarus Ventures, LLC

Clarus Ventures, LLC acts as the investment adviser to a series of pooled life‑sciences funds (for example, the Clarus Lifesciences and Clarus Defined Exit series) and manages roughly $1.0 billion in regulatory assets on behalf of those funds rather than providing individualized advice to retail clients. The adviser focuses on investments across healthcare, pharmaceutical, biotechnology, medical devices and life‑sciences tools, making and overseeing pooled vehicle investments and related portfolio company activities.

The firm’s investment approach emphasizes structured, often late‑stage life‑sciences financings — including corporate partnerships, pre‑approval royalty monetizations and opportunistic Collaboration Investments — and combines fundamental, technical and cyclical research with centralized investment‑committee approval. Clarus uses dedicated processes and specialized resources (Development Companies and Therapeutic Platform Teams) to source, diligence, structure and monitor transactions, with regular internal meetings and semi‑annual in‑person portfolio reviews described in the brochure.

A notable aspect of Clarus is its integration within the Blackstone group: the brochure identifies Blackstone Inc. as the ultimate parent and discusses connections with Blackstone’s insurance‑facing businesses, banking counterparties and capital markets/broker‑dealer activities (including BXCI/BXCI‑related exemptive frameworks). Those corporate affiliations, and related strategic relationships, shared platform resources and data services, are highlighted in the Brochure as factors that can affect deal sourcing, co‑investment allocations, custody arrangements and the management of potential conflicts of interest.